Lenigron (Timolol, Bimatoprost)

Timolol reduces the production of aqueous humor by blocking beta‑adrenergic receptors in the ciliary body, while Bimatoprost increases the outflow of fluid through the uveoscleral pathway. The dual mechanism provides a more pronounced reduction in intra‑ocular pressure than either agent alone.

The dosing regimen for Lenigron is determined by the prescribing clinician based on the patient’s intra‑ocular pressure, response to therapy, and overall ocular health. The prescriber will provide specific instructions on the number of drops and frequency.

Safety data for Lenigron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Lenigron product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenigron combines a beta‑blocker and a prostaglandin analog, offering a two‑pronged approach to pressure reduction. Compared with monotherapy agents, the combination can achieve greater intra‑ocular pressure lowering, potentially reducing the need for multiple separate drops.

Lenigron should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contaminated.

Lenigron is applied as an ocular drop. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. Avoid touching the tip of the bottle to the eye or any surface.

Serious risks include severe allergic reactions, significant worsening of glaucoma, systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm, and rare ocular complications like corneal ulceration or uveitis. Patients should seek immediate medical attention if they experience these symptoms.

Lenigron is contraindicated in patients with known hypersensitivity to timolol, bimatoprost, or any component of the formulation, as well as in individuals with severe asthma, chronic obstructive pulmonary disease, or certain cardiac conditions where systemic beta‑blockade could be harmful.